Search results for "immunosuppressive agent"

showing 10 items of 282 documents

Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.

2001

Background Controlled trials have firmly established the need for immunosuppressive therapy in autoimmune hepatitis. However, reports about long-term management and prognosis of the disease are scarce. Patients and methods We reviewed the charts of 103 consecutive patients with a well-documented long-term course of autoimmune hepatitis who had been carefully managed over a mean observation period of 95 months (12-405 months). Results Under immunosuppressive therapy 94 patients (91.2%) reached complete remission after a mean treatment duration of 3 +/- 3 months. 28 of the 103 patients (27.2%) were eligible for a trial of treatment withdrawal after a mean treatment duration of 32.2 months (ra…

AdultMalePediatricsmedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentBiopsyPrednisoloneAzathioprineAutoimmune hepatitisLiver transplantationPharmacotherapyLiver Function TestsAzathioprineMedicineHumansChildCyclophosphamideAgedRetrospective StudiesAutoimmune diseaseHepatitismedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLong-Term CareSurgeryHepatitis AutoimmuneLiverDrug Therapy CombinationFemalebusinessLiver function testsImmunosuppressive Agentsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct

Evaluation of domino liver transplantations in Germany.

2013

Summary A retrospective multicenter study has been conducted to evaluate domino liver transplantations (DLTs) in Germany. The study provides insight into survival and features having an impact on the assessment of neuropathy after DLT. In addition, a neurologic follow-up program with a scheme to estimate the likelihood of de novo amyloidosis is presented. A series of 61 DLTs at seven transplant centers in Germany was enrolled. The mean age of domino recipients at the time of transplantation was 58 years, 46 of them being men, and 15 being women. The median follow-up was 46 months. The overall 1-, 3-, and 5-year survival of domino recipients was 81.6%, 70.8% and 68.8%, respectively. Causes o…

AdultMalePediatricsmedicine.medical_specialtyDominoDiabetes mellitusGermanymedicineLiving DonorsHumansAgedRetrospective StudiesTransplantationAmyloid Neuropathies Familialbusiness.industryAmyloidosisMean ageAmyloidosisMiddle Agedmedicine.diseasePost transplantSurgeryLiver TransplantationTransplantationMulticenter studyHepatocellular carcinomaFemalebusinessImmunosuppressive AgentsFollow-Up StudiesTransplant international : official journal of the European Society for Organ Transplantation
researchProduct

Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA tr…

2019

Background: In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA). Aims: To evaluate health-related quality of life (HRQoL) in APPRECIA trial. Methods: HRQoL was evaluated using disease-specific shortened Spanish version of the IBDQ (SIBDQ-9) and generic European Quality of Life-5 Dimensions (EQ-5D) questionnaires, completed at baseline and at weeks 24 and 52. Results: Sixty-one patients (37 ADA and 24 AZA) had evaluable data for HRQoL. Patients treated with ADA or AZA had significant improvement from baseline to weeks 24 and 52 in SIBDQ-9 and EQ-5D (p < 0.001 and p = 0.006 for all comparisons…

AdultMaleQuality of lifemedicine.medical_specialtyPostoperative therapyAzathioprinePostoperative recurrence03 medical and health sciences0302 clinical medicineCrohn DiseaseQuality of lifeRecurrenceSurveys and QuestionnairesInternal medicineAzathioprineAdalimumabHumansMedicineIn patientPostoperative PeriodCrohn's diseaseHepatologybusiness.industryRemission InductionGastroenterologyAdalimumabSpanish versionProphylactic drug therapymedicine.diseaseEndoscopes GastrointestinalCrohn's diseaseSpain030220 oncology & carcinogenesisQuality of LifeFemale030211 gastroenterology & hepatologyIntestinal resectionbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Hand-assisted laparoscopic living-donor nephrectomy versus open surgery: evaluation of surgical trauma and late graft function in 82 patients

2009

Abstract Objective We evaluated and quantified surgical trauma and late graft function in cases of hand-assisted laparoscopic living-donor nephrectomy (HALLDN) versus open living-donor nephrectom (OLDN). Methods This study is a retrospective nonrandomized single-center analysis. Between 1995 and January 2008, 82 patients with end-stage renal disease received kidney transplantations from living donors. Open living-donor nephrectomy was performed in 37 donors, and 45 underwent laparoscopic hand-assisted nephrectomy. Demographic data and perioperative and postoperative data, such as markers of acute phase (C-reactive protein; serum amyloid A) and biochemical markers of glomerular filtration (s…

AdultMaleRENAL-FUNCTIONmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentRenal functionNephrectomySettore MED/24 - UrologiaKIDNEYmedicineLiving DonorsHumansMinimally Invasive Surgical ProceduresCystatin CLaparoscopyKidney transplantationRetrospective StudiesCOMPLICATIONSOUTCOMESTransplantationSerum Amyloid A ProteinWarm Ischemia Timemedicine.diagnostic_testbusiness.industryPerioperativeMiddle Agedmedicine.diseaseKidney TransplantationNephrectomySurgeryEndoscopyTransplantationkidney transplantation laparoscopy nephrectomyC-Reactive ProteinRENAL-FUNCTION COMPLICATIONS EXPERIENCE OUTCOMES KIDNEY SAFETYSAFETYCreatinineEXPERIENCESurgeryFemaleLaparoscopybusinessImmunosuppressive AgentsGlomerular Filtration Rate
researchProduct

Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study

2017

Abstract Background The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant (IS) drugs. Methods We performed a cohort study including MS patients recruited at the Neurological Department of the University of Palermo. Mean follow-up period was ten years for the whole cohort. We calculated cancer incidence among patients treated with IS. Incidence rates were compared in the cohort by calculating the relative risk according to length and dose of exposure to IS. Cancer incidence among MS patients was compared to cancer incidence in the general…

AdultMaleRiskmedicine.medical_specialtyMultiple SclerosisPopulationlcsh:RC346-429Cohort StudiesYoung Adult03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicinemedicineHumansMultiple sclerosiCancer; Cohort study; Immunosuppressant; Multiple sclerosis; Treatment; Neurology (clinical)Prospective cohort studyeducationlcsh:Neurology. Diseases of the nervous systemCancerImmunosuppressanteducation.field_of_studybusiness.industryIncidenceMultiple sclerosisCancerRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment030220 oncology & carcinogenesisRelative riskCohortFemaleNeurology (clinical)Cohort studybusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleCohort studyBMC Neurology
researchProduct

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplant…

2001

We investigated whether a T cell-reduced allogeneic stem cell transplant (SCT) with minimal conditioning and subsequent donor lymphocyte infusions (DLI) could reduce the incidence and severity of GVHD while retaining stable engraftment. Five patients with hematological malignancies (three MM, one CLL, one Chediak-Higashi syndrome) were conditioned with TBI (200 cGy). One patient additionally received fludarabine (120 mg/m(2)). CsA and mofetyl-mycophenolate (MMF) were administered to prevent GVHD. All patients were grafted with >3 x 10(6)/kg highly purified CD34(+) cells together with 2 x 10(6)/kg CD3(+) cells (three patients) or 1 x 10(5)/kg CD3(+) cells (two patients). Quick hematopoietic …

AdultMaleTime FactorsLymphocyte TransfusionT-LymphocytesT cellLymphocyteChronic lymphocytic leukemiamedicine.medical_treatmentHematopoietic stem cell transplantationLymphocyte DepletionFatal OutcomemedicineHumansTransplantation HomologousTreatment FailureTransplantation ChimeraTransplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedMycophenolic Acidmedicine.diseaseLeukemia Lymphocytic Chronic B-CellPeripheral stem cell transplantationFludarabineTransplantationmedicine.anatomical_structureHematologic NeoplasmsLymphocyte TransfusionImmunologyCyclosporineFemaleChediak-Higashi SyndromeMultiple MyelomabusinessImmunosuppressive AgentsVidarabineWhole-Body IrradiationFollow-Up Studiesmedicine.drugBone Marrow Transplantation
researchProduct

Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with …

2019

Background Conflicting data have been published as to the risk of cytomegalovirus (CMV) DNAemia and CMV disease in patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide. Methods We conducted a multicenter retrospective study including 118 patients subjected to unmanipulated haplo-HSCT to further clarify this issue. An historic cohort comprising 165 patients undergoing other transplant modalities (HLA-matched related, matched unrelated or mismatched) was built for comparison purposes. Plasma CMV DNA monitoring was performed using two highly sensitive real-time PCR assays. Results Overall, the cumulative incidence of…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentCyclophosphamidemedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusHematopoietic stem cell transplantationYoung AdultInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceCyclophosphamideAgedRetrospective StudiesTransplantationbusiness.industryIncidenceIncidence (epidemiology)Hematopoietic Stem Cell Transplantationvirus diseasesRetrospective cohort studyCmv dnaemiaMiddle AgedViral Loadmedicine.diseasesurgical procedures operativeInfectious DiseasesSpainCytomegalovirus InfectionsDNA ViralCohortFemalebusinessImmunosuppressive Agentsmedicine.drugTransplant Infectious Disease
researchProduct

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients

2011

Tacrolimus is a substrate of cytochrome P4503A (CYP3A) enzymes as well as of the drug transporter ABCB1. We have investigated the possible influence of CYP3A5 and ABCB1 single nucleotide polymorphisms (SNPs) and other factors (e.g. albumin, hematocrit and steroids) on tacrolimus blood levels achieved in a population of Caucasian liver (n=51) and kidney (n=50) transplant recipients. At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels (C0) were recorded and the weight-adjusted tacrolimus dosage (mg/kg/day) was calculated. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for genotyping CYP3A5*1 and *3 …

AdultMalemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentDNA Mutational AnalysisPopulationSingle-nucleotide polymorphismLiver transplantationBiologyKidneyPolymorphism Single NucleotideGastroenterologyBiomarkers PharmacologicalTacrolimusWhite PeopleGene FrequencyInternal medicineGeneticsmedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1educationAllele frequencyAllelesKidney transplantationAgededucation.field_of_studyKidney metabolismGeneral MedicineMiddle Agedmedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationTransplantationsurgical procedures operativeItalyLiverImmunologySettore BIO/14 - FarmacologiaPharmacogenetics CYP3A5 ABCB1 TacrolimusTransplant patientsFemaleImmunosuppressive AgentsPolymorphism Restriction Fragment LengthInternational Journal of Molecular Medicine
researchProduct

Clinical activity after fingolimod cessation: Disease reactivation or rebound?

2018

Background and purpose There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Methods Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. Results A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%…

AdultMalemedicine.medical_specialtyAdolescentDiseaseCohort StudiesMultiple sclerosisImmunosuppressive AgentYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrenceInternal medicineHumansMedicine030212 general & internal medicineFingolimod; Multiple sclerosis; Reactivation; Rebound; Neurology; Neurology (clinical)Natural courseReboundFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseReactivationMagnetic Resonance ImagingFingolimodDiscontinuationItalyWithholding TreatmentNeurologymultiple sclerosiCohortFemaleNeurology (clinical)Cohort StudiebusinessImmunosuppressive Agents030217 neurology & neurosurgeryHumanmedicine.drug
researchProduct

Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoprolif…

2010

Long term immunosuppression and therapy of acute rejections result in a 20-120-fold increased risk to develop Non Hodgkin lymphoma (NHL). Since immunosuppressive therapy and immunological disorders are major risk factors for the development of NHL in the non-transplant population we aimed to analyze risk factors for PTLD in our cohort of liver transplanted (LT) patients.We analyzed retrospectively 431 patients liver transplanted between 1998 and 2008.PTLD was diagnosed in eleven of 431 patients (2.6%). PTLD, especially late PTLD, was significantly more frequent in patients who received steroids before LT (Kaplan-Meier: p0.001). Moreover PTLD in immunocompromised patients with preoperative s…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPopulationAutoimmune hepatitisKaplan-Meier EstimateLiver transplantationGastroenterologyYoung AdultPostoperative ComplicationsRisk Factorshemic and lymphatic diseasesInternal medicinePreoperative CareInternal MedicinemedicineCadaverHumansProspective cohort studyeducationChildAgedProportional Hazards ModelsRetrospective StudiesHepatitiseducation.field_of_studybusiness.industryLymphoma Non-HodgkinRetrospective cohort studyImmunosuppressionMiddle Agedmedicine.diseaseTissue DonorsLymphomaLiver TransplantationHepatitis Autoimmunesurgical procedures operativeImmunologyMultivariate AnalysisFemaleSteroidsbusinessImmunosuppressive AgentsEuropean journal of internal medicine
researchProduct